Figure 2.

In vivo activity of erlotinib with or without radiotherapy (RT) in tumor xenografts. H226 (10⁶) or UM-SCC6 (10⁶) cells were injected subcutaneously into the flanks of athymic mice as described. Mice were treated with erlotinib (0.8 mg daily via oral gavage), RT (2-Gy fraction twice per week), or the combination for 3 weeks. Points, mean tumor size (mm³; six mice per treatment group). Reprinted with permission from Chinnaiyan et al. (2005, Figure 6).